Skip to main content
Premium Trial:

Request an Annual Quote

MDx, Omics Tools Stocks Beat Broader Stock Market in June

NEW YORK (GenomeWeb) – The GenomeWeb Index of 31 firms operating in the molecular diagnostics and omics tools industries beat the broader stock market in June with four of the firms providing a double-digit increase in their stock prices.

Overall, the GenomeWeb Index climbed 2 percent month over month, compared to 2 percent declines for both the Dow Jones Industrial Average and the Nasdaq, and beating the Nasdaq Biotech Index, which closed up slightly more than 1 percent month over month.

Leading the way among firms in the GenomeWeb Index was Bio-Reference Laboratories. The firm, whose stock gained 24 percent, inked a deal early in June to be acquired by Opko Health for around $1.47 billion. The terms of the deal value BRL's shares at $52.58.

The other top gainers for the month included Cepheid (+11 percent), Exact Sciences (+10 percent), and NanoString Technologies (+10 percent).

Cepheid's shares gained momentum at the end of the month and were upgraded to a Buy rating and $75 price target by Craig-Hallum Capital Group. Though Cepheid's shares were trading near a 52-week high as of the end of June, in afternoon trading today its stock was down around 5 percent at $58.04.

Late in June, Exact Sciences forecast 21,000 completed Cologuard tests for the second quarter, above earlier expectations of 18,000 tests for its flagship product.

NanoString hit a 52-week high of $16.40 on June 24, though there were no obvious catalysts for the jump in stock price. However, in late May it inked a companion diagnostics deal with Merck.

Sequenom led decliners, falling 9 percent month over month. During June, a US Court of Appeals upheld an earlier district court decision that invalidated a key patent covering circulating cell-free DNA, which is employed in the company's noninvasive prenatal test.

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.